CLINICAL TRIALS PROFILE FOR TRANDOLAPRIL
✉ Email this page to a colleague
All Clinical Trials for TRANDOLAPRIL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000558 ↗ | Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1995-11-01 | To determine whether the addition of angiotensin converting enzyme (ACE) inhibitor to standard therapy in patients with known coronary artery disease and preserved left ventricular function will prevent cardiovascular mortality and reduce the risk of myocardial infarction. |
| NCT00133692 ↗ | INVEST: INternational VErapamil SR Trandolapril STudy | Completed | Abbott | Phase 4 | 1997-09-01 | Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA). |
| NCT00133692 ↗ | INVEST: INternational VErapamil SR Trandolapril STudy | Completed | University of Florida | Phase 4 | 1997-09-01 | Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA). |
| NCT00212901 ↗ | High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy | Completed | Ottawa Hospital Research Institute | N/A | 2004-08-01 | Investigation of wheather addition of angiotensin receptor blocker (Irbesartan) to recommended doses of angiotensin converting enzyme inhibitor (trandolapril) is more effective in decreasing amount of protein in urine in patients with diabetic kidney disease than high doses of trandolapril. |
| NCT00233532 ↗ | Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL) | Completed | Abbott | Phase 4 | 2004-03-01 | The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients. |
| NCT00234871 ↗ | Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) | Completed | Abbott | Phase 4 | 2004-01-01 | The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy |
| NCT00235014 ↗ | A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT) | Completed | Abbott | Phase 4 | 1997-03-01 | The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRANDOLAPRIL
Condition Name
Clinical Trial Locations for TRANDOLAPRIL
Trials by Country
Clinical Trial Progress for TRANDOLAPRIL
Clinical Trial Phase
Clinical Trial Sponsors for TRANDOLAPRIL
Sponsor Name
